Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Ingrid A. Boere"'
Autor:
Phyllis van der Ploeg, Cynthia SE. Hendrikse, Anna MJ. Thijs, Hans M. Westgeest, Huberdina PM. Smedts, M Caroline Vos, Mathilde Jalving, Christianne AR. Lok, Ingrid A. Boere, Maaike APC. van Ham, Petronella B. Ottevanger, Anneke M. Westermann, Constantijne H. Mom, Roy I. Lalisang, Sandrina Lambrechts, Ruud LM. Bekkers, Jurgen MJ. Piek
Publikováno v:
Heliyon, Vol 10, Iss 1, Pp e23170- (2024)
Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular signature. There remains a high unmet need for alter
Externí odkaz:
https://doaj.org/article/ec80d08ac0c84967956ced20e2dd05ff
Autor:
Jonathan Servayge, Ester P. Olthof, Constantijne H. Mom, Maaike A. van der Aa, Hans H. B. Wenzel, Jacobus van der Velden, Remi A. Nout, Ingrid A. Boere, Helena C. van Doorn, Heleen J. van Beekhuizen
Publikováno v:
Cancers, Vol 16, Iss 3, p 635 (2024)
Aim: To investigate and compare overall survival (OS), disease-free survival (DFS) and toxicity of women who underwent either chemoradiotherapy with or without prior lymph node debulking or upfront chemotherapy followed by radiotherapy and hypertherm
Externí odkaz:
https://doaj.org/article/4b9e5a4f00484d7c9ea0c6c8e164a94a
Autor:
Eleni Karamouza, Rosalind M. Glasspool, Caroline Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B. Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A. Boere, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Cécile Proust-Lima, Xavier Paoletti
Publikováno v:
Cancers, Vol 15, Iss 6, p 1823 (2023)
(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients’ monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged indi
Externí odkaz:
https://doaj.org/article/3d6ea15b1a234135a95e0b9e7a424411
Autor:
Gatske M. Nieuwenhuyzen-de Boer, Malika Kengsakul, Ingrid A. Boere, Helena C. van Doorn, Heleen J. van Beekhuizen
Publikováno v:
Cancers, Vol 15, Iss 1, p 72 (2022)
Background: Patients with unresectable disease during cytoreductive surgery (CRS) for advanced-stage ovarian cancer are underreported. Knowledge of treatment and survival after surgery is limited. The aim of this study is to address the knowledge gap
Externí odkaz:
https://doaj.org/article/43f9304b0bd044268380f83766d85beb
Autor:
Chris J. de Witte, Joachim Kutzera, Arne van Hoeck, Luan Nguyen, Ingrid A. Boere, Mathilde Jalving, Petronella B. Ottevanger, Christa van Schaik-van de Mheen, Marion Stevense, Wigard P. Kloosterman, Ronald P. Zweemer, Edwin Cuppen, Petronella O. Witteveen
Publikováno v:
Cancers, Vol 14, Iss 6, p 1511 (2022)
The majority of patients with ovarian cancer ultimately develop recurrent chemotherapy-resistant disease. Treatment stratification is mainly based on histological subtype and stage, prior response to platinum-based chemotherapy, and time to recurrent
Externí odkaz:
https://doaj.org/article/9ff70052c2ff4029ab872a302aec9dc5
Autor:
Anouk Corbeau, Remi A. Nout, Jan Willem M. Mens, Nanda Horeweg, Jérémy Godart, Ellen M. Kerkhof, Sander C. Kuipers, Mariette I. E. van Poelgeest, Judith R. Kroep, Ingrid A. Boere, Helena C. van Doorn, Mischa S. Hoogeman, Uulke A. van der Heide, Hein Putter, Marij J. P. Welters, Sjoerd H. van der Burg, Carien L. Creutzberg, Stephanie M. de Boer
Publikováno v:
Cancers, Vol 13, Iss 20, p 5179 (2021)
External beam radiation therapy (EBRT) with concurrent chemotherapy followed by brachytherapy is a very effective treatment for locally advanced cervical cancer (LACC). However, treatment-related toxicity is common and reduces the patient’s quality
Externí odkaz:
https://doaj.org/article/d341305a04fe4fd289b98eefee29523e
Autor:
Leni van Doorn, Mandy M. van Rosmalen, Wendy M. van der Deure, Esther Oomen-de Hoop, Robert Porrazzo, Sophie M. Wijngaard, Ingrid A. Boere, Paola Veenstra, Eman Ibrahim, Peter de Bruijn, Lena E. Friberg, Stijn L. W. Koolen, Ron H. J. Mathijssen, Agnes Jager
Publikováno v:
Cancers, Vol 13, Iss 15, p 3915 (2021)
Chemotherapy-induced alopecia (CIA), a side effect with high impact, can be prevented by cooling the scalp during the administration of some cytotoxic drugs. However, the effects of this prolonged scalp cooling on the pharmacokinetics of chemotherapy
Externí odkaz:
https://doaj.org/article/614a1a0671f746f2b22b173b61731ad0
Autor:
Claudia Berends, Charlotte Maggen, Christianne A. R. Lok, Mathilde van Gerwen, Ingrid A. Boere, Vera E. R. A. Wolters, Kristel Van Calsteren, Heidi Segers, Marry M. van den Heuvel-Eibrink, Rebecca C. Painter, Mina Mhallem Gziri, Frédéric Amant
Publikováno v:
Cancers, Vol 13, Iss 6, p 1214 (2021)
Data on the use of Granulocyte colony-stimulating factor (G-CSF) in pregnant cancer patients are scarce. The International Network of Cancer, Infertility and Pregnancy (INCIP) reviewed data of pregnant patients treated with chemotherapy and G-CSF, an
Externí odkaz:
https://doaj.org/article/80d178fceb5e4181a47e44dea070c877
Autor:
Silvia R. Vitale, Floris H. Groenendijk, Ronald van Marion, Corine M. Beaufort, Jean C. Helmijr, Hendrikus Jan Dubbink, Winand N. M. Dinjens, Patricia C. Ewing-Graham, Ramon Smolders, Helena C. van Doorn, Ingrid A. Boere, Els M. J. J. Berns, Jozien Helleman, Maurice P. H. M. Jansen
Publikováno v:
Biomolecules, Vol 10, Iss 3, p 415 (2020)
The aim of this study was to determine an optimal workflow to detect TP53 mutations in baseline and longitudinal serum cell free DNA (cfDNA) from high-grade serous ovarian carcinomas (HGSOC) patients and to define whether TP53 mutations are suitable
Externí odkaz:
https://doaj.org/article/76c9e3e5ee1348d4b952b7c5f009f099
Autor:
Joosje H. Heimovaara, Ingrid A. Boere, Jorine de Haan, Kristel van Calsteren, Frédéric Amant, Lia van Zuylen, Christine A.R. Lok, C.A.R. Lok, L. van Zuylen, I.A. Boere, F. Amant, C.C.M. Beerendonk, M. Bellido-Casado, J.J. Beltman, M.E.M.M. Bos, J.J. Duvekot, C.G., Gerestein, S. Gordijn, C.J.M. de Groot, M. van Grotel, S.N. Han, B.C. Heeres, M.M. van den Heuvel-Eibrink, A. Houwink, D.R. Huitema, PhW. Koken, L.B. Koppert, P.J. Lugtenburg, P.B. Ottevanger, R.C. Painter, P.M.P. Poortmans, E.M. Roes, L. van der Scheer, C.P. Schröder, B.B.M. Suelmann, K.P.M. Suijkerbuijk, G. van Tienhoven, N.E. van Trommel, J.W. Trum, J. van der Velden, I.J.H. Vriens, P.O. Witteveen
Publikováno v:
Heimovaara, J H, Boere, I A, de Haan, J, van Calsteren, K, Amant, F, van Zuylen, L, Lok, C A R, the Dutch Advisory Board for Cancer during Pregnancy, Lok, C A R, van Zuylen, L, Boere, I A, Amant, F, Beerendonk, C C M, Bellido-Casado, M, Beltman, J J, Bos, M E M M, Duvekot, J J, Gerestein, C G, Gordijn, S, de Groot, C J M, van Grotel, M, Han, S N, Heeres, B C, van den Heuvel-Eibrink, M M, Houwink, A, Huitema, D R, Koken, P, Koppert, L B, Lugtenburg, P J, Ottevanger, P B, Painter, R C, Poortmans, P M P, Roes, E M, van der Scheer, L, Schröder, C P, Suelmann, B B M, Suijkerbuijk, K P M, van Tienhoven, G, van Trommel, N E, Trum, J W, van der Velden, J, Vriens, I J H & Witteveen, P O 2022, ' Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands ', European Journal of Cancer, vol. 171, pp. 13-21 . https://doi.org/10.1016/j.ejca.2022.04.040
European Journal of Cancer, 171, 13-21. Pergamon
European Journal of Cancer, 171, 13-21. Elsevier Ltd.
European Journal of Cancer, 171, 13-21. ELSEVIER SCI LTD
European Journal of Cancer, 171, 13-21
European Journal of Cancer, 171, pp. 13-21
European Journal of Cancer, 171, 13-21. Elsevier Limited
European Journal of Cancer, 171, 13-21. Pergamon
European Journal of Cancer, 171, 13-21. Elsevier Ltd.
European Journal of Cancer, 171, 13-21. ELSEVIER SCI LTD
European Journal of Cancer, 171, 13-21
European Journal of Cancer, 171, pp. 13-21
European Journal of Cancer, 171, 13-21. Elsevier Limited
Contains fulltext : 252036.pdf (Publisher’s version ) (Closed access) BACKGROUND: Most physicians encounter pregnant women with cancer incidentally, leading to a lack of expertise or confidence to inform and treat these patients based on the most r